Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe psoriasis: Findings from the phase 3 POETYK PSO-3 and PSO-4 trials

被引：0

作者：

Foley, Peter ^{[1
,2
]}

Zhang, Jianzhong ^{[3
]}

Imafuku, Shinichi ^{[4
]}

Ding, Yangfeng ^{[5
]}

Okubo, Yukari ^{[6
]}

Li, Hui ^{[7
]}

Tada, Yayoi ^{[8
]}

Li, Linfeng ^{[9
]}

Ohtsuki, Mamitaro ^{[10
]}

Pan, Weili ^{[11
]}

Lu, Yan ^{[12
]}

Hao, Cheng ^{[13
]}

Xian, Jiang ^{[14
]}

Ho, Ji-Chen ^{[15
]}

Guo, Shuping ^{[16
]}

Seo, Seong Jun ^{[17
]}

Napoli, Andrew ^{[18
]}

Chatterjee, Arkendu ^{[18
]}

Kisa, Renata M. ^{[18
]}

Banerjee, Subhashis ^{[18
]}

Morita, Akimichi ^{[19
]}

机构：

[1] Univ Melbourne, St Vincents Hosp Melbourne, Prob Med Res, Melbourne, Vic, Australia

[2] Skin Hlth Inst, Melbourne, Vic, Australia

[3] Peking Univ, Peoples Hosp, Beijing, Peoples R China

[4] Fukuoka Univ Hosp, Fukuoka, Japan

[5] Shanghai Skin Dis Hosp, Shanghai, Peoples R China

[6] Tokyo Med Univ, Tokyo, Japan

[7] Chongqing Med Univ, Affiliated Hosp 1, Shanghai, Peoples R China

[8] Teikyo Univ, Sch Med, Tokyo, Japan

[9] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China

[10] Jichi Med Univ, Shimotsuke, Tochigi, Japan

[11] Peoples Hosp Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China

[12] Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China

[13] Zhejiang Univ, Sir Run Shaw Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China

[14] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China

[15] Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan

[16] Shanxi Med Univ, Hosp 1, Jinzhong, Shanxi, Peoples R China

[17] Chung Ang Univ Hosp, Seoul, South Korea

[18] Bristol Myers Squibb, New York, NY USA

[19] Nagoya City Univ, Grad Sch Med Sci, Nagoya, Japan

来源：

AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：28 / 29

页数：2

共 50 条

[21] Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
Armstrong, April W.
Augustin, Matthias
Beaumont, Jennifer L.
Pham, Tan P.
Hudgens, Stacie
Gordon, Kenneth B.
Zhuo, Joe
Becker, Brandon
Zhong, Yichen
Kisa, Renata M.
Banerjee, Subhashis
Papp, Kim A.
DERMATOLOGY AND THERAPY, 2024, 14 (08) : 2235 - 2248
[22] Deucravacitinib (DEUC), an Oral, Selective Tyrosine Kinase 2 ( TYK2) Inhibitor, Versus Placebo (PBO) and Apremilast (APR) in Moderate to Severe Plaque Psoriasis: Safety Analysis by Prior Therapy Subgroups in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Eyerich, Kilian
Warren, Richard B.
Blauvelt, Andrew
Gudjonsson, Johann
Sobell, Jeffrey
Banerjee, Subhashis
Balagula, Eugene
Hippeli, Lauren
Gooderham, Melinda
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 120 - 120
[23] Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies
Armstrong, April W.
Strober, Bruce
Gordon, Kenneth
Zhuo, Joe
Becker, Brandon
Kisa, Renata
Throup, John
Kim, Jonghyeon
Dirschka, Thomas
Papp, Kim Alexander
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 24 - 25
[24] Deucravacitinib Improves Dermatology Life Quality Index (DLQI) in Patients with Moderate to Severe Psoriasis: Results fromthe Phase 3 POETYK PSO-1 and PSO-2 Trials
Augustin, Matthias
Strober, Bruce
Armstrong, April
Beaumont, Jennifer
Pham, Tan
Hudgens, Stacie
Zhuo, Joe
Becker, Brandon
Banerjee, Subhashis
Kisa, Renata
Papp, Kim
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 112 - 112
[25] Deucravacitinib in moderate to severe plaque psoriasis: Correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2
Rubel, Diana
Armstrong, April W.
Papp, Kim
Zhuo, Joe
Becker, Brandon
Zhong, Yichen
Beaumont, Jennifer
DeRosa, Michael
Kisa, Renata M.
Banerjee, Subhashis
Strober, Bruce
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 71 - 72
[26] Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)
Strober, Bruce
Blauvelt, Andrew
Warren, Richard B.
Papp, Kim A.
Armstrong, April W.
Gordon, Kenneth B.
Morita, Akimichi
Alexis, Andrew F.
Lebwohl, Mark
Foley, Peter
Kisa, Renata M.
Colston, Elizabeth
Wang, Tao
Banerjee, Subhashis
Thaci, Diamant
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (08) : 1543 - 1554
[27] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis: safety profile in older (≥ 65 years) and younger (< 65 years) patients in the phase III POETYK PSO-1, PSO-2 and long-term extension trials
Kearney, Niamh
Pink, Andrew
Hoyt, Kim
Kisa, Renata M.
Banerjee, Subhashis
Rogers, Alexandra
Mullan, Jill
Warren, Richard B.
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I60 - I61
[28] Deucravacitinib, an Oral, Allosteric, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis in POETYK PSO-1 and POETYK PSO-2: Effect on Joint Pain and Peripheral Joint Disease vs Placebo and Apremilast
Merola, Joseph
Mease, Philip J.
Armstrong, April W.
Strand, Vibeke
Lehman, Thomas
Choi, Jiyoon
Becker, Brandon
Zhong, Yichen
Colombo, Matthew J.
Thaci, Diamant
Bili, Androniki
Gottlieb, Alice B.
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4462 - 4465
[29] Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Moderate to Severe Psoriasis: Long-Term Efficacy in Placebo Crossovers
Warren, Richard B.
Lebwohl, Mark
Imafuku, Shinichi
Bagel, Jerry
Armstrong, April W.
Passeron, Thierry
Linaberry, Misti
Hoyt, Kim
Napoli, Andrew
Kisa, Renata M.
Thaci, Diamant
Blauvelt, Andrew
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4346 - 4348
[30] Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in psoriasis: Reductions in individual component scores and body regions of the Psoriasis Area and Severity Index in the phase 3 POETYK PSO-1 and PSO-2 trials
Sobell, Jeffrey M.
Eyerich, Kilian
Blauvelt, Andrew
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB41 - AB41

← 1 2 3 4 5 →